FDA Press Releases About Name-Brand GLP-1s: What You Should Know

You were scrolling through your newsfeed and a headline stopped you. Something about the FDA and GLP-1 medications. Maybe it sounded confusing. Maybe you weren’t sure whether it affected your treatment.

FDA press releases are primarily written for regulators, health systems, and pharmacists, as opposed to patients who just want to understand their weight loss medication. The language is often technical. Context can feel lacking. As with any news story, the headlines rarely tell you everything you’d like to know..

This article breaks down several significant FDA actions from 2025 and 2026 and whether they affect name-brand GLP-1 medications. And it’s all in plain, easy-to-understand language, including what changed, what it may mean, and what to ask your licensed healthcare provider if you want to know more.

‍

Key Takeaways: Recent FDA Announcements Don’t Affect Name-Brand GLP-1s

• In August 2025, the FDA approved the first generic injectable GLP-1 medication for weight loss, creating new lower-cost access pathways.
• In December 2025, the FDA approved the first oral GLP-1 pill specifically for chronic weight management. 
• FDA-approved GLP-1 medications—including Wegovy®, Ozempic®, Mounjaro®, and Zepbound®—were not impacted by the 2025–2026 enforcement actions targeting unlicensed, unapproved sellers of GLP-1s.
• When you see a scary GLP-1 headline, the first question may be, does it apply to FDA-approved medications? In many recent cases, it does not.
• Contact your care team or licensed healthcare provider if any FDA announcement raises questions about your treatment.

‍

‍

Is FDA news raising questions about your weight loss plan? Get Thin MD can help you make sense of it.

[BIG CTA GRAPHIC/BUTTON HERE]

‍

‍

3 Important FDA Announcements on GLP-1 Medications (2025–2026)

The FDA issued multiple press releases and statements about GLP-1 medications over the past 18 months. We organized them into 3 categories.

Category 1: New approvals that expand your weight loss medication options.

In December 2025, the FDA approved oral Wegovy® for chronic weight management in adults with obesity. Before this approval, FDA-approved GLP-1 medications for weight management were injectables. The oral option changed that.

Separately, the FDA also approved the first generics (a prescription drug that has the same active-ingredient formula as a brand-name drug) for injectable GLP-1 medication. 

• Generic Saxenda (liraglutide): approved for weight management.
• Generic Victoza (liraglutide) & Generic Byetta (exenatide): injections, both approved for blood sugar control.

These generics meet the same FDA standards for safety and effectiveness as the name-brand product.

Category 2: Enforcement changes to protect the market (and consumers).

In February 2026, the FDA announced it would take action against companies selling unapproved GLP-1 products. 

These were products sold without FDA review, falsely labeled as GLP-1 medications, never tested for safety or effectiveness, and in some cases, imported with dangerous ingredients. This action had no impact on FDA-approved brand name GLP-1 medications. 

Category 3: Import safety protocols to help stop potentially dangerous ingredients from reaching consumers.

In September 2025, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from entering the US. 

This is supply chain protection, helping to ensure that the ingredients used in any GLP-1 product meet quality and safety standards before they reach US consumers.

‍

What “FDA Approved” Means, and Why It Protects You

The phrase “FDA approved” is used so often it can start to feel meaningless. But the review process behind it is extensive.

When the FDA approves a medication, the organization has reviewed:

• Clinical trial data demonstrating the medication is safe and effective for its intended use.
• Safety data collected across a broad patient population.
• The manufacturing process—how the medication is produced and quality-controlled.
• Labeling—what claims can and cannot be made.
• Post-market surveillance requirements—ongoing safety monitoring after approval.

For FDA-approved GLP-1 medications, this process can take years. It often involves thousands of study participants and extensive regulatory review before medication is accessible to the public.

FDA approval is rarely a one-time event. After approval, the FDA continues to collect safety data, review adverse event reports, and update labeling when new information emerges. This is why the FDA issues safety communications even for approved medications.

‍

Approval of Oral Wegovy® for Weight Management 

Before oral Wegovy® was approved by the FDA, every FDA-approved GLP-1 medication for weight management required a subcutaneous injection. The oral approval in December 2025 changed that. 

The approved product is once-daily oral semaglutide that typically starts at a dosage of 1.5 mg and escalates over 90 days.

For people already tolerating an injectable GLP-1, there may be no medical reason to switch to the Wegovy® pill. 

For people who avoided GLP-1 treatment because of injections, consider having a conversation with a licensed healthcare provider to see if the Wegovy® pill is an appropriate option for you. 

Here are a few important things to understand about the oral option:

• The Wegovy® pill has different dosing requirements than injectable GLP-1 medication. For example, the pill must be taken on an empty stomach. 
• Effectiveness may differ between oral and injectable forms. A licensed healthcare provider will review your medical history to determine which option is better for you.
• Cost for the oral version may differ from the injectable version.
• A prescription from a licensed healthcare provider is required for either form.

‍

Why the FDA’s Action Against Unapproved Products Is Often Considered A Good Thing

Some of the recent headlines may sound as if the FDA is cracking down on GLP-1 medications broadly. The FDA’s February 2026 enforcement actions specifically targeted:

• Companies selling products falsely labeled as GLP-1 medications that were never reviewed by the FDA for safety or effectiveness.
• Products containing untested “salt forms” of GLP-1 medications (chemical variations that may not have the same chemical and pharmacologic properties as the active ingredient in the approved medication).
• Products marketed for “research purposes” but sold directly to consumers for weight loss without a valid prescription.
• Imported products using potentially dangerous active pharmaceutical ingredients.

None of these apply to Ozempic®, Wegovy®, Mounjaro®, or Zepbound®. These name-brand GLP-1 medications passed the FDA’s rigorous approval process. The enforcement action was about protecting the market from products that had not.

The FDA also established a “green list” import alert in 2026—a screening system to flag potentially dangerous GLP-1 ingredients at the US border before they can reach consumers.

For people using FDA-approved GLP-1 medications, the 2026 enforcement actions represent the system working correctly to protect the quality of the market, not to restrict access to legitimate GLP-1 options.

‍

Understanding FDA Headlines & What They Mean

Not all FDA communications mean the same thing. Here is a simple guide to what each type of announcement may actually signal.

• “FDA Approves [drug] for [condition]”

A new medication or new use has been reviewed and cleared. 

• “FDA Takes Action Against [seller or product type]”

Read carefully. Who specifically is being named? Ask: is this about FDA-approved medications or a different category of product? In the 2025–2026 cycle, enforcement actions targeted unlicensed sellers, not FDA-approved brand name medications.

• “FDA Issues Safety Communication About [drug name]”

This tends to mean new data has been collected and reviewed. Thus, the FDA is sharing updated information about a medication already on the market. This does not necessarily mean the medication is being withdrawn. It may mean the monitoring system simply caught something worth communicating. If you’re concerned, mention it to your licensed healthcare provider at your next check-in.

• “FDA Updates Labeling for [drug name]”

A label update typically reflects new findings, new approved uses, or updated safety guidance. Your licensed healthcare provider may already be aware of label changes for your medication and can explain what, if anything, changes for you.

‍

What a Review of 13 Recent FDA GLP-1 Announcements Reveals

We reviewed FDA press releases, formal announcements, and safety communications specifically mentioning GLP-1 medications between January 2024 and May 2026. 

We then broke those announcements down by type (along with links so you can review the information yourself):

New approvals and label expansions: 4 announcements

• FDA Approves First New Molecular Entity Under National Priority Voucher Program 
• FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes
• FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide 
• FDA Approves First Medication for Obstructive Sleep Apnea 

Safety communications and post-market monitoring updates: 4 announcements 

• FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications
• Update on FDA’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
• FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss 
• FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List 

Enforcement actions targeting unlicensed or unapproved products: 3 announcements 

• FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs 
• FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients 
• FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s 

Policy clarifications for pharmacies and compounders: 2 announcements 

• FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize 
• FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products 

Of the announcements reviewed, none directly restricted access to FDA-approved brand name GLP-1 medications. 

From our perspective, the FDA’s regulatory attention has been primarily focused on expanding access through new approvals and protecting quality through enforcement, as opposed to restricting legitimate treatment.

For people using FDA-approved GLP-1 medications like Ozempic®, Wegovy®, Mounjaro®, or Zepbound®, access has continued to remain the same.

‍

Frequently Asked Questions About FDA Announcements on GLP-1 Medications

Q: Why does the FDA keep making announcements about GLP-1 medications?

GLP-1 medications are popular prescription medications. A drug category as popular as GLP-1s may require more regulatory activity—more approvals, more safety monitoring, and more enforcement against potential safety risks to consumers. FDA announcements keep consumers and providers informed.

Q: What is the latest announcement about GLP-1 drugs?

There have been several, none of which affect name-brand medications. Recent announcements include December 2025 approvals of the first oral GLP-1 pill for obesity, and the first generic injectable GLP-1; as well as February 2026 enforcement actions against unlicensed sellers. 

Q: Does an FDA safety communication mean I should stop my medication?

Probably not, but talk to your licensed healthcare provider. A safety communication means the FDA has new data to share about a medication already on the market. It does not necessarily mean the medication is being withdrawn or that you need to stop. Your licensed healthcare provider can review the specific communication and explain what, if anything, it means for your treatment. 

‍

Why Get Thin MD

Get Thin MD is a national telehealth weight loss program. When you begin your journey with us, a licensed healthcare provider will review your medical history to determine if you are eligible for GLP-1 treatment. 

When you work with Get Thin MD, you get:

• A licensed healthcare provider review of your full medical history.

• Guidance on what your medication options are.
• Care Coaches available 7 days a week.
• Access to Registered Dietitians to help you build healthy habits that support your treatment.
• No insurance required, and no in-person visits needed.

This May Not Be the Right Moment to Start If...

A GLP-1 medication may not be appropriate for everyone, regardless of FDA approvals. A licensed healthcare provider consultation will review if:

• You have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (GLP-1 medications may carry contraindications here).
• You are pregnant or planning to become pregnant.
• You have a history of pancreatitis (this requires a careful provider discussion before starting any GLP-1 medication).
• You are not ready to make lifestyle changes alongside medication. GLP-1 treatment is a tool alongside nutritional and behavioral support.

When to Talk to Your Licensed Healthcare Provider

If you see an FDA announcement about GLP-1 medications, bring these questions to your next check-in:

• “Does this announcement apply to the specific medication I’m taking?”
• “Should I make any changes to my treatment based on this news?”
• “Are there any new FDA-approved options I should know about, like the oral Wegovy® pill approved in December 2025?” 
• “If I’ve had concerns about cost or access, what options are available to me now?”

For full safety details, always visit our Important Safety Information page.

‍

‍

Ready to find a weight loss approach that works with your life? Start your consultation with Get Thin MD, no insurance required.

[BIG CTA GRAPHIC/BUTTON HERE]

‍

‍

The Bottom Line

FDA press releases can be difficult to translate for some. For people using FDA-approved GLP-1 medications like Ozempic®, Wegovy®, Mounjaro®, or Zepbound®, an important thing to know is this: the FDA enforcement actions mentioned in this article target a different category of product. Your name-brand medication was not restricted by the aforementioned FDA actions.

‍

Important Safety Information

Get Thin connects customers with licensed providers who may prescribe medication through state-licensed pharmacies. Prescription medication only available if prescribed after an online consultation, as applicable, with a healthcare provider. Physicians may prescribe compounded medications as needed to meet medical necessity or drug shortages. The FDA does not review or approve any compounded medications for safety or effectiveness. Results may vary. Please visit the Important Safety Information page.

‍